Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2020 / N 3

Прямые оральные антикоагулянты при неклапанной фибрилляции предсердий: реальная клиническая практика
М.М. Руда, Ю.А. Карпов

References

1. Federal Law "On the Circulation of Medicines " dated 2010 Apr 12 No. 61-FZ (latest version). Available from: http://www.consultant.ru/document/cons_doc_LAW_99350/ Accessed 2021 Feb 02. (In Russian).
2. Research in real clinical practice. Kolbin AS, editor. Moscow: OKI, Buki Vedi; 2020. 208 p. (In Russian).
3. Peterson ED, Pokorney SD. New treatment options fail to close the anticoagulation gap in atrial fibrillation. Journal of the American College of Cardiology 2017 May;69(20):2485-7.
4. Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant therapy in elderly patients with atrial fibrillation. Kardiologiia 2018;58(10):45-52 (In Russian).
5. Panchenko EP, Akseta G, Libis RA, Miller ON, Novikova TN, Nagibovich OA. Risk factors and prescribed antithrombotic therapy in patients with newly diagnosed non-valvular atrial fibrillation in the Russian Federation: based on the results of the international GARFIELD-AF registry. Kardiologiia 2017;57(4):38-44 (In Russian).
6. Radha B, Sayganov SA, Gromyko TYu. Atrial fibrillation in patients with inferior myocardial infarction. Bulletin of II Mechnikov North-Western State Medical University 2015;7(1):46-52 (In Russian).
7. Stepina EV, Lukyanov MM, Bichurina MA, Belova EA, Kudryashov EV, Yuzkov YuV, Boytsov SA. Oral anticoagulants in ambulatory and in-hospital treatment of patients with atrial fibrillation associated with hypertension, ischemic heart disease and chronic heart failure: data from hospital registry RECVASA-CLINICA. Rational Pharmacotherapy in Cardiology 2017;13(2):146-54 (In Russian).
8. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, Malouf JF, Ammash NM, Friedman PA, Somers VK. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004 Jul;110(4):364-7.
9. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Lévy P, Kalman JM, Sanders P. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. JAMA Cardiology 2018 Jun;3(6):532-40.
10. Novikova TN, Ashurov AB, Kiseleva MV, Plotnikova MO, Podoprigora EA, Sayganov SA, Khagush AL. Stroke prevention in patients with atrial fibrillation in clinical practice: emphasis on efficacy and safety of anticoagulant therapy. Kardiologiia 2020;60(4):54-61 (In Russian).
11. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poçi D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case–control study. European Heart Journal 2013 Apr;34(14):1061-7.
12. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998 Sep;98(10):946-52.
13. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. The American Journal of Medicine 2002 Oct;113(5):359-64.
14. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003 Aug;290(8):1049-56.
15. Shakhmatova OO, Panchenko EP. Apixaban in treatment of patients with atrial fibrillation. Atherothrombosis 2015;1:52-64 (In Russian).
16. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2009 Sep;361(12):1139-51.
17. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine 2011 Sep;365(10):883-91.
18. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi H, Ansell J, Atar D, Avezum A, Bahit C, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2011 Sep;365(11):981-92.
19. Ministry of Healthcare of the Russian Federation; Russian Society of Cardiology. Atrial fibrillation and flutter: clinical guidelines. Coding according to the International Statistical Classification of Diseases and Health Problems: I48. 0 I48.1 I48.2 I48.3 I48.4 I48.9. Age group: adults. Year of approval: 2020. Available from: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf Accessed 2021 Feb 02. (In Russian).
20. Hindricks G, Potpara T, Dagres N, Bax JJ, Blomstr@öm-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, Meir ML, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal 2020 Aug 29;ehaa612. doi: 10.1093/eurheartj/ehaa612. Online ahead of print.
21. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2013 Nov;369(22):2093-104.
22. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 2016 Oct;37(38):2893-962.
23. Ministry of Healthcare of the Russian Federation. Instructions for the medical use of the drug Eliquis® (Eliquis®). Registration certificate LP-002007 dated 2020 Aug 07. Available from: https://www.pfizerprofi.ru/sites/default/files/eliquis_5mg_lld_2020.pdf Accessed 2021 Feb 02. (In Russian).
24. Drazen JM. Drazen’s dozen: articles that changed practice since 2000. The New England Journal of Medicine 2019 May; 32 p. Available from: https://cdn.nejm.org/pdf/Drazens-Dozen.pdf Accessed 2021 Feb 02.
25. Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, Hu M, Illoh O, Wei Y, Goulding MR, Chillarige Y, Southworth MR, MaCurdy TE, Kelman JA. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. The American Journal of Medicine 2019 May;132(5):596-604.e11.
26. Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thrombosis and Haemostasis 2017 Jun;117(6):1072-82.
27. Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin K, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Annals of Internal Medicine 2020 Apr;172(7):463-73.
28. Van Ganse E, Danchin N, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Lefevre C, Cotté FE, Gollety S, Falissard B, Belhassen M, Steg PG. Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: the NAXOS study. Stroke 2020 Jul;51(7):2066-75.
29. Karpov YuA. Efficacy and safety of apixaban in patients with non-valvular atrial fibrillation in real clinical practice in Russia. Atmosphere. News of Cardiology 2018;4:3-12 (In Russian).
30. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. European Heart Journal 2018 Jan;4(1):59-68.
31. McCullough PA, Ball T, Cox KM, Assar MD. Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: pro. Clinical Journal of American Society of Nephrology 2016 Nov;11(11):2079-84.
32. Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation 2020 Apr;141(17):1384-92.
33. Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis. Pacing and Clinical Electrophysiology 2018 Jun;41(6):627-34.
34. Noseworthy P, Yao X, Tangri N, Shah N, Nath K. Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease. European Heart Journal 2017 Aug;38(1 Suppl):1213-4.
35. Kislyak OA, Atakanova AN, Taras ES, Kasatova TB. Antithrombotic therapy in patients with chronic coronary syndromes and atrial fibrillation in real clinical practice. Lechebnoye Delo 2020;4:28-37 (In Russian).

  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]